Cytosorbents (CTSO)
(Delayed Data from NSDQ)
$1.55 USD
+0.13 (9.16%)
Updated Sep 20, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Cytosorbents Corporation [CTSO]
Reports for Purchase
Showing records 1 - 20 ( 186 total )
Company: Cytosorbents Corporation
Industry: Medical - Products
Focus Remains on DrugSorb-ATR FDA Filing; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
Looking Ahead to DrugSorb-ATR Filing and PuriFi Launch; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
DrugSorb-ATR Filing Expected By 3Q24; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Full Phase 3 Results at AATS Meeting in April; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
Phase 3 Ticagrelor Removal Study Misses Primary Endpoint; Downgrade to Neutral With $1.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: STAR-T Trial Update: Mixed Data. Increasing Our Risk (r) from 15% to 30%, Lowers Our Price Target from $10 to $4
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: Post Covid Hangover- Adjusting Estimates, Price Target Goes to $10
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Major Clinical Readout Expected Around Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: Data on Ex Vivo Organ Perfusion in Recent Publication
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
All Eyes on STAR-T Results Before Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: Reports 2nd Quarter Results - Pivotal Data by Year End
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: DSMB Recommends Complete STAR-T No Modifications Needed
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
STAR-T Results in 2H23 Could Be a Major Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: STAR-T Trial Reaches 2nd Milestone at N
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: Reports 4th Quarter and Full Year 2022 Results
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Returning to Growth in 2023; STAR-T Results By Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S